Literature DB >> 1890304

The generation of immunogenic peptides can be selectively increased or decreased by proteolytic enzyme inhibitors.

L Vidard1, K L Rock, B Benacerraf.   

Abstract

The ability of splenic APC and a B cell hybridoma (LS.102.9) to process and present OVA to a panel of T-T hybridomas with different fine specificities was investigated. Splenic APC process and present OVA to all the T-T hybrids. The B cell hybridoma could similarly process and present OVA to some T-T hybrids but was very inefficient in stimulating two of the T cell hybridomas. The presentation of native OVA to these two T-T hybrids was significantly increased by leupeptin. Pulsing experiments demonstrated that leupeptin acted on the APC at a step before the processed Ag was displayed on the cell surface in association with MHC molecules. Leupeptin has no effect on the presentation of OVA peptides by LS.102.9 to the T-T hybrids. Leupeptin inhibits the generation of the epitopes of OVA that LS.102.9 produces under basal conditions. We also surveyed the effect of other protease inhibitors and observed similar augmenting and inhibitory effects on the presentation of selected OVA epitopes. The augmentation of processing by a protease inhibitor indicates that in the lysosomal/endosomal compartment proteases have capacity to both generate and destroy immunogenic peptides. Our data suggest that protease inhibitors could potentially be used as immunomodulators and are discussed in terms of physiology of the lysosomal/endosomal compartment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1890304

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

Review 1.  Human cartilage proteoglycans as T cell autoantigens.

Authors:  J A Goodacre; J P Pearson
Journal:  Ann Rheum Dis       Date:  1992-09       Impact factor: 19.103

2.  HLA-DP, HLA-DQ, and HLA-DR have different requirements for invariant chain and HLA-DM.

Authors:  Marcel van Lith; Rosanna M McEwen-Smith; Adam M Benham
Journal:  J Biol Chem       Date:  2010-10-19       Impact factor: 5.157

Review 3.  Understanding the focused CD4 T cell response to antigen and pathogenic organisms.

Authors:  Jason M Weaver; Andrea J Sant
Journal:  Immunol Res       Date:  2009-02-07       Impact factor: 2.829

4.  Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation.

Authors:  J Deussing; W Roth; P Saftig; C Peters; H L Ploegh; J A Villadangos
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

5.  Intestinal epithelial cells use two distinct pathways for HLA class II antigen processing.

Authors:  R M Hershberg; P E Framson; D H Cho; L Y Lee; S Kovats; J Beitz; J S Blum; G T Nepom
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

Review 6.  Drug delivery issues in vaccine development.

Authors:  M F Powell
Journal:  Pharm Res       Date:  1996-12       Impact factor: 4.200

7.  An l- to d-Amino Acid Conversion in an Endosomolytic Analog of the Cell-penetrating Peptide TAT Influences Proteolytic Stability, Endocytic Uptake, and Endosomal Escape.

Authors:  Kristina Najjar; Alfredo Erazo-Oliveras; Dakota J Brock; Ting-Yi Wang; Jean-Philippe Pellois
Journal:  J Biol Chem       Date:  2016-12-06       Impact factor: 5.157

8.  Processing and presentation of an antigen of Mycobacterium avium require access to an acidified compartment with active proteases.

Authors:  M A Holsti; P M Allen
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

Review 9.  Physiological functions of endosomal proteolysis.

Authors:  T Berg; T Gjøen; O Bakke
Journal:  Biochem J       Date:  1995-04-15       Impact factor: 3.857

10.  FcepsilonRI-mediated antigen endocytosis turns interferon-gamma-treated mouse mast cells from inefficient into potent antigen-presenting cells.

Authors:  C Tkaczyk; I Villa; R Peronet; B David; S Mécheri
Journal:  Immunology       Date:  1999-06       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.